S 3578 sulfate
S 3578 sulfate is a broad-spectrum antibacterial agent, particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) (MIC = 0.78-3.13 μg/mL) and Pseudomonas aeruginosa (MIC = 1.56-6.25 μg/mL). S 3578 sulfate can be used in the research of infectious conditions.
For research use only. We do not sell to patients.
- CAS No.: 474949-70-7
- Formula: C24H30N10O9S3
- Molecular Weight:698.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Chemical Information
-
CAS No. 474949-70-7
-
Molecular Weight 698.75
-
Formula C24H30N10O9S3
-
SMILES
[O-]S(=O)(O)=O.OC(C1=C(C[N+]2=C3C(N(CCCNC)C=N3)=CC=C2)CS[C@@]([C@@H]4NC(/C(C5=NSC(N)=N5)=N\OCC)=O)([H])N1C4=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Yoshizawa H, et al. New broad-spectrum parenteral cephalosporins exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Part 2: Synthesis and structure-activity relationships in the S-3578 series. Bioorg Med Chem. 2004 Aug 1;12(15):4211-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
S 3578 sulfate Related Classifications
HY-105523 Related Classifications
Powered by Bioz